Table 1.
Baseline demographics and disease characteristics of the patients
| Study period | Induction period | Maintenance period | |||
|---|---|---|---|---|---|
| Placebo | Mirikizumab | Mirikizumab 250 mg/placebo | Mirikizumab 250 mg/mirikizumab 125 mg | Mirikizumab 250 mg/mirikizumab 250 mg | |
| Number | 107 | 423 | 91 | 90 | 91 |
| Age (years) | 45·7 (13·7) | 46·4 (13·6) | 43·8 (13·5) | 46·9 (13·3) | 45·6 (13·7) |
| Male, n (%) | 74 (69·2) | 299 (70·7) | 61 (67) | 64 (71) | 59 (65) |
| Weight (kg) | 86·5 (22·9) | 84·7 (21·0) | 83·9 (23·7) | 84·3 (20·4) | 82·8 (18·0) |
| < 100, n (%) | 87 (81·3) | 344 (81·3) | 76 (84) | 76 (84) | 76 (84) |
| ≥ 100, n (%) | 20 (18·7) | 79 (18·7) | 15 (16) | 14 (16) | 15 (16) |
| Geographical distribution, n (%) | |||||
| North America | 21 (19·6) | 84 (19·9) | 23 (25) | 16 (18) | 23 (25) |
| Other | 86 (80·4) | 339 (80·1) | 68 (75) | 74 (82) | 68 (75) |
| Prior biologic therapy, n (%) | 31 (29·0) | 139 (32·9) | 34 (37) | 26 (29) | 33 (36) |
| Psoriasis duration (years) | 17·0 (10·9) | 17·7 (11·5) | 18·9 (11·2) | 17·0 (11·8) | 17·6 (11·8) |
| Baseline psoriatic arthritis, n (%) | 8 (7·5) | 69 (16·3) | 12 (13) | 13 (14) | 15 (16) |
| sPGA, n (%) | |||||
| sPGA = 3 | 49 (45·8) | 212 (50·1) | 46 (51) | 45 (50) | 44 (48) |
| sPGA = 4 | 45 (42·1) | 178 (42·1) | 42 (46) | 41 (46) | 38 (42) |
| sPGA = 5 | 13 (12·1) | 33 (7·8) | 3 (3) | 4 (4) | 9 (10) |
| % BSA | 31·9 (19·4) | 31·3 (20·3) | 27·3 (16·1) | 31·8 (21·8) | 31·7 (21·2) |
| PASI | 23·5 (10·1) | 22·3 (9·8) | 20·7 (7·1) | 22·6 (9·7) | 22·6 (10·5) |
| PSS | 22·4 (10·7) | 23·3 (10·5) | 22·6 (11·3) | 22·4 (10·3) | 23·9 (11·0) |
| DLQI | 13 (7·0) | 14·4 (7·4) | 14·9 (7·7) | 14·0 (7·6) | 14·1 (7·3) |
Data are presented as the mean (SD) unless otherwise stated. BSA, body surface area; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; PSS, Psoriasis Symptoms and Signs; sPGA, static Physician’s Global Assessment.